Literature DB >> 18662240

Extended total mesorectal excision in locally advanced rectal cancer (T4a) and the clinical role of MRI-evaluated neo-adjuvant downstaging.

S G Larsen1, J N Wiig, H L Emblemsvaag, K K Grøholt, K H Hole, A Bentsen, S Dueland, T Vetrhus, K-E Giercksky.   

Abstract

OBJECTIVE: To compare the clinical ability of MRl taken before and after neo-adjuvant treatment in locally advanced rectal cancer (LARC) to predict the necessary extension of TME (ETME) and the possibility to achieve a R0 resection.
METHOD: Prospective registration of 92 MRI evaluated T4a cancers undergoing elective surgery between 2002 and 2007 in a tertiary referral centre for multimodal treatment of rectal cancer.
RESULTS: MRI identified patients in need of neo-adjuvant treatment and predicted T-downstaging in 10% and N-downstaging in 59%. Seventy-nine percent R0 resections, 18% R1 and 3% R2 were obtained after ETME in 95% of the patients and TME in the rest. Higher tumour regression grade (TRG) was achieved in higher ypT-stage (P < 0.01). Preoperative chemo radiotherapy resulted in that more patients obtained TRG1-3 compared to those receiving radiotherapy (79% vs. 57%, P = 0.02). The pelvic wall was the area of failure in 70% of the R1 resections. Tumour cells outside the mesorectal fascia scattered within fibrosis was found in 18 TRG2-3 among 33 ypT4 tumours (55%).
CONCLUSION: MRl cannot discriminate tumour within fibrosis. Therefore, if a R0 resection is the goal, we advocate optimal surgery in accordance with the pre-treatment MRI. Post treatment MRI is a poor predictor of final histology and should not be relied upon to guide the extent of surgical resection. The study has initiated a new approach to histopathological classification of the removed specimen where we introduce a MRI assisted technique for investigating the areas at risk outside the mesorectal fascia in the specimen.

Entities:  

Mesh:

Year:  2008        PMID: 18662240     DOI: 10.1111/j.1463-1318.2008.01649.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  4 in total

Review 1.  Magnetic resonance imaging in rectal cancer: a surgeon's perspective.

Authors:  Avanish P Saklani; Sung Uk Bae; Amy Clayton; Nam Kyu Kim
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

2.  The Feasibility and Efficacy of Laparoscopic Extended Total Mesorectal Excision for Locally Advanced Lower Rectal Cancer.

Authors:  Takashi Nonaka; Akiko Fukuda; Kyoichiro Maekawa; Shigeki Nagayoshi; Takayuki Tokunaga; Mitsutoshi Takatsuki; Tomoo Kitajima; Ken Taniguchi; Hikaru Fujioka
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

3.  Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.

Authors:  Marie Grøn Saelen; Anne Hansen Ree; Alexandr Kristian; Karianne Giller Fleten; Torbjørn Furre; Helga Helseth Hektoen; Kjersti Flatmark
Journal:  Radiat Oncol       Date:  2012-09-27       Impact factor: 3.481

4.  Machine learning-based multiparametric MRI radiomics for predicting poor responders after neoadjuvant chemoradiotherapy in rectal Cancer patients.

Authors:  Jia Wang; Jingjing Chen; Ruizhi Zhou; Yuanxiang Gao; Jie Li
Journal:  BMC Cancer       Date:  2022-04-19       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.